To determine whether RRM2 expression and functionality is altered and, if so, which aspect is affected in C9 ALS/FTD, we first performed a Western blot using post-mortem motor cortex tissue and compared RRM2 protein levels in C9 ALS/FTD patients with those in non-neurodegenerative controls. This evidence concerns the gene RRM2 and frontotemporal dementia.